ArticleBMC oral health2026
Drug-associated oropharyngeal infection: a real-world pharmacovigilance study using the FDA adverse event reporting system database.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveDrug-associated oropharyngeal infection represents a common yet frequently overlooked safety concern in clinical practice, potentially increasing patient discomfort, prolonging hospitalization, and elevating healthcare burdens. However, there is a lack of large-scale, systematic real-world studies comprehensively identifying the implicated drugs. This study investigated the primary drugs associated with oropharyngeal infection reports in the FDA Adverse Event Reporting System (FAERS) to assess their potential risk and to provide references for clinical risk identification and monitoring.
methodsWe reviewed publicly available FAERS data from the first quarter (Q1) of 2004 to the second quarter (Q2) of 2025. Disproportionality analyses were performed using the Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), the Medicines and Healthcare Products Regulatory Agency (MHRA) algorithm, the Bayesian Confidence Propagation Neural Network (BCPNN), and the Multi-item Gamma Poisson Shrinker (MGPS) to process and analyze reports of drugs associated with oropharyngeal infection.
resultsFrom Q1 2004 to Q2 2025, FAERS recorded 75,512 reports of oropharyngeal infection. Reports involving male patients were significantly higher than those for female patients. We identified 69 high-risk drugs of oropharyngeal infection, of which 43 were not mentioned in their prescribing information. According to Anatomical Therapeutic Chemical (ATC) classification, the category with the highest risk was L04 (Immunosuppressants). The median time to onset of oropharyngeal infection was 45 days (interquartile range [IQR] 4-317). Analysis using the Weibull shape parameter (WSP) indicated an early failure-type profile.
conclusionsThis study highlights key drugs with significant disproportionality signals for drug-associated oropharyngeal infection and underscores the importance of early risk assessment and close monitoring, particularly during the initial treatment phase. These findings contribute to a better understanding of drug-associated oropharyngeal infections and provide a basis for future research into their underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.